If we are looking at this solely in terms of ingredient coverage, Id agree.
If we are looking at this in terms of $$$:gains for the time period youve stacked these...meh.
Agreed, SERM doses too high.
In the future you may also want to consider aromasin/exemestane as your AI, as adex is contraindicated with nolva and will be a poor ancilliary if needed during PCT.
A statement like that needs some qualifiers.
If clomid is causing libido issues:
1) dose is too high (not necessarily e2)
2) may need AI (e2/SHBG high)
3) clomid may just not be for you
Also keep mind, PCT can be a volatile period regardless of SERM.
I dunno. All these studies show to me is what is possible if you follow sh1t PCT practices.
Lots of guys believe if any compound is gonna fuk you over its trestolone. Ive heard of long recoveries following it but no-one has ever reported it fuking them over.
Therefore, rainbows.
Theres degrees of risk.
Even a study cant guarantee you that X will occur given Y and Z.
All you can do is assess the risks, and decide from there what odds you are personally prepared to go up against and do your best to minimise those risks.
^yes, exactly. Youre currently transitioning from an environment where some semblance of balance was occuring (meaning you had no sides), to a new one where 2 key variables responsible for that balance have suddenly been removed and a new one introduced.
I doubt clomid is solely responsible for...
For sure.
Our goal with e2 is always about control, right? You are already attempting to do that right now; you should continue to do so through PCT.
There is a real possibility for increased e2 due to clomid, especially at the doses youre going to run. High e2 during PCT is absolutely not...
If youre going to dose clomid at 25mg+ then yes Id keep on the aromasin. Also, its generally not a good idea to stop an AI cold turkey when PCT starts.
Do you have any experience with clomid?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.